These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Rhinitis medicamentosa in cytological assessment of the nasal mucosa]. Tarchalska B; Gotlib T; Samoliński B Pol Merkur Lekarski; 2005 Sep; 19(111):288-90. PubMed ID: 16358845 [TBL] [Abstract][Full Text] [Related]
3. [Clinical review of 33 cases of rhinitis medicamentosa by decongestant nasal spray]. Yuta A; Ogawa Y Arerugi; 2013 Dec; 62(12):1623-30. PubMed ID: 24608651 [TBL] [Abstract][Full Text] [Related]
4. Rhinitis medicamentosa: what an otolaryngologist needs to know. Doshi J Eur Arch Otorhinolaryngol; 2009 May; 266(5):623-5. PubMed ID: 19096862 [TBL] [Abstract][Full Text] [Related]
5. [Pathologic conditions associated with drug-induced rhinitis]. Milosević D; Janosević L; Dergenc R; Vasić M Srp Arh Celok Lek; 2004; 132(1-2):14-7. PubMed ID: 15227959 [TBL] [Abstract][Full Text] [Related]
6. Rhinitis medicamentosa: a nationwide survey of Canadian otolaryngologists. Fowler J; Chin CJ; Massoud E J Otolaryngol Head Neck Surg; 2019 Dec; 48(1):70. PubMed ID: 31818321 [TBL] [Abstract][Full Text] [Related]
7. [The rebound of nasal resistance after decongestant used in nose]. Shen J; Huang X; Xiang J; Shu H Lin Chuang Er Bi Yan Hou Ke Za Zhi; 1999 Dec; 13(12):560-1. PubMed ID: 12541428 [TBL] [Abstract][Full Text] [Related]
8. Rebound congestion and rhinitis medicamentosa: nasal decongestants in clinical practice. Critical review of the literature by a medical panel. Mortuaire G; de Gabory L; François M; Massé G; Bloch F; Brion N; Jankowski R; Serrano E Eur Ann Otorhinolaryngol Head Neck Dis; 2013 Jun; 130(3):137-44. PubMed ID: 23375990 [TBL] [Abstract][Full Text] [Related]
9. Rhinitis medicamentosa: a review of causes and treatment. Graf P Treat Respir Med; 2005; 4(1):21-9. PubMed ID: 15725047 [TBL] [Abstract][Full Text] [Related]
10. Severe Rhinitis Medicamentosa Successfully Treated with Rhinolight® Endonasal UV Phototherapy. Carson P; Lyons M Ir Med J; 2019 Feb; 112(2):874. PubMed ID: 30875167 [TBL] [Abstract][Full Text] [Related]
11. [Research progress on rhinitis medicamentosa]. Wang YN; Luan ZL; Wang HT Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2017 Nov; 52(11):872-875. PubMed ID: 29141305 [TBL] [Abstract][Full Text] [Related]
12. Long-term use of oxy- and xylometazoline nasal sprays induces rebound swelling, tolerance, and nasal hyperreactivity. Graf P Rhinology; 1996 Mar; 34(1):9-13. PubMed ID: 8739860 [TBL] [Abstract][Full Text] [Related]
13. Rhinitis medicamentosa: the forgotten factor in nasal obstruction. Mabry RL South Med J; 1982 Jul; 75(7):817-9. PubMed ID: 6178170 [TBL] [Abstract][Full Text] [Related]
14. One-week use of oxymetazoline nasal spray in patients with rhinitis medicamentosa 1 year after treatment. Graf P; Hallén H ORL J Otorhinolaryngol Relat Spec; 1997; 59(1):39-44. PubMed ID: 9104748 [TBL] [Abstract][Full Text] [Related]
16. Management of Rhinitis Medicamentosa: A Systematic Review. Zucker SM; Barton BM; McCoul ED Otolaryngol Head Neck Surg; 2019 Mar; 160(3):429-438. PubMed ID: 30325708 [TBL] [Abstract][Full Text] [Related]
17. Increased frequency of rhinitis medicamentosa due to media advertising for nasal topical decongestants. Archontaki M; Symvoulakis EK; Hajiioannou JK; Stamou AK; Kastrinakis S; Bizaki AJ; Kyrmizakis DE B-ENT; 2009; 5(3):159-62. PubMed ID: 19902852 [TBL] [Abstract][Full Text] [Related]